Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.
Identifieur interne : 001711 ( PubMed/Corpus ); précédent : 001710; suivant : 001712Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.
Auteurs : F. Mauguière ; E. Broussolle ; J. IsnardSource :
- Electroencephalography and clinical neurophysiology [ 0013-4694 ]
English descriptors
- KwdEn :
- Aged, Analysis of Variance, Apomorphine (therapeutic use), Brain (physiopathology), Brain Mapping, Electric Stimulation, Electroencephalography, Evoked Potentials, Somatosensory (physiology), Female, Humans, Male, Median Nerve (physiopathology), Middle Aged, Movement Disorders (drug therapy), Movement Disorders (etiology), Movement Disorders (physiopathology), Muscle Rigidity (drug therapy), Muscle Rigidity (etiology), Muscle Rigidity (physiopathology), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Reaction Time (physiology), Syndrome.
- MESH :
- chemical , therapeutic use : Apomorphine.
- complications : Parkinson Disease.
- drug therapy : Movement Disorders, Muscle Rigidity, Parkinson Disease.
- etiology : Movement Disorders, Muscle Rigidity.
- physiology : Evoked Potentials, Somatosensory, Reaction Time.
- physiopathology : Brain, Median Nerve, Movement Disorders, Muscle Rigidity, Parkinson Disease.
- Aged, Analysis of Variance, Brain Mapping, Electric Stimulation, Electroencephalography, Female, Humans, Male, Middle Aged, Syndrome.
Abstract
Among early cortical median nerve SEPs the frontal N30 potential is known to show amplitude reduction during execution of voluntary movements and to be abnormally reduced in parkinsonian patients. However, it is not clear whether N30 abnormalities are related to the severity of motor disability in Parkinson's disease. To address this question we studied median nerve SEPs, using a 16-channel montage, in 7 patients chronically treated with subcutaneous (s.c.) injections of apomorphine hydrochloride for spontaneous "on-off" motor fluctuations. We observed no significant changes in the latency, amplitude or scalp topography of early SEPs when comparing traces and maps obtained in the "off" condition and during the "on" phase induced by s.c. injection of apomorphine. The absence of any SEP changes, despite a clear-cut relief of the akinetic-rigid syndrome, suggests that early cortical SEPs, and in particular the frontal N30 potential, at least when recorded in a subject at rest, are not usable as an objective means to assess the severity or the fluctuations of motor disability in Parkinson's disease.
PubMed: 7688279
Links to Exploration step
pubmed:7688279Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.</title><author><name sortKey="Mauguiere, F" sort="Mauguiere, F" uniqKey="Mauguiere F" first="F" last="Mauguière">F. Mauguière</name><affiliation><nlm:affiliation>Department of Functional Neurology and Epileptology, Hôpital Neurologique, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name></author><author><name sortKey="Isnard, J" sort="Isnard, J" uniqKey="Isnard J" first="J" last="Isnard">J. Isnard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1993 Jul-Aug</MedlineDate></PubDate></date><idno type="RBID">pubmed:7688279</idno><idno type="pmid">7688279</idno><idno type="wicri:Area/PubMed/Corpus">001711</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001711</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.</title><author><name sortKey="Mauguiere, F" sort="Mauguiere, F" uniqKey="Mauguiere F" first="F" last="Mauguière">F. Mauguière</name><affiliation><nlm:affiliation>Department of Functional Neurology and Epileptology, Hôpital Neurologique, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name></author><author><name sortKey="Isnard, J" sort="Isnard, J" uniqKey="Isnard J" first="J" last="Isnard">J. Isnard</name></author></analytic><series><title level="j">Electroencephalography and clinical neurophysiology</title><idno type="ISSN">0013-4694</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Apomorphine (therapeutic use)</term><term>Brain (physiopathology)</term><term>Brain Mapping</term><term>Electric Stimulation</term><term>Electroencephalography</term><term>Evoked Potentials, Somatosensory (physiology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Median Nerve (physiopathology)</term><term>Middle Aged</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Movement Disorders (physiopathology)</term><term>Muscle Rigidity (drug therapy)</term><term>Muscle Rigidity (etiology)</term><term>Muscle Rigidity (physiopathology)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Reaction Time (physiology)</term><term>Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term><term>Muscle Rigidity</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term><term>Muscle Rigidity</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Evoked Potentials, Somatosensory</term><term>Reaction Time</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Median Nerve</term><term>Movement Disorders</term><term>Muscle Rigidity</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Brain Mapping</term><term>Electric Stimulation</term><term>Electroencephalography</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Syndrome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Among early cortical median nerve SEPs the frontal N30 potential is known to show amplitude reduction during execution of voluntary movements and to be abnormally reduced in parkinsonian patients. However, it is not clear whether N30 abnormalities are related to the severity of motor disability in Parkinson's disease. To address this question we studied median nerve SEPs, using a 16-channel montage, in 7 patients chronically treated with subcutaneous (s.c.) injections of apomorphine hydrochloride for spontaneous "on-off" motor fluctuations. We observed no significant changes in the latency, amplitude or scalp topography of early SEPs when comparing traces and maps obtained in the "off" condition and during the "on" phase induced by s.c. injection of apomorphine. The absence of any SEP changes, despite a clear-cut relief of the akinetic-rigid syndrome, suggests that early cortical SEPs, and in particular the frontal N30 potential, at least when recorded in a subject at rest, are not usable as an objective means to assess the severity or the fluctuations of motor disability in Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7688279</PMID><DateCreated><Year>1993</Year><Month>09</Month><Day>07</Day></DateCreated><DateCompleted><Year>1993</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-4694</ISSN><JournalIssue CitedMedium="Print"><Volume>88</Volume><Issue>4</Issue><PubDate><MedlineDate>1993 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Electroencephalography and clinical neurophysiology</Title><ISOAbbreviation>Electroencephalogr Clin Neurophysiol</ISOAbbreviation></Journal><ArticleTitle>Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>243-54</MedlinePgn></Pagination><Abstract><AbstractText>Among early cortical median nerve SEPs the frontal N30 potential is known to show amplitude reduction during execution of voluntary movements and to be abnormally reduced in parkinsonian patients. However, it is not clear whether N30 abnormalities are related to the severity of motor disability in Parkinson's disease. To address this question we studied median nerve SEPs, using a 16-channel montage, in 7 patients chronically treated with subcutaneous (s.c.) injections of apomorphine hydrochloride for spontaneous "on-off" motor fluctuations. We observed no significant changes in the latency, amplitude or scalp topography of early SEPs when comparing traces and maps obtained in the "off" condition and during the "on" phase induced by s.c. injection of apomorphine. The absence of any SEP changes, despite a clear-cut relief of the akinetic-rigid syndrome, suggests that early cortical SEPs, and in particular the frontal N30 potential, at least when recorded in a subject at rest, are not usable as an objective means to assess the severity or the fluctuations of motor disability in Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mauguière</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Functional Neurology and Epileptology, Hôpital Neurologique, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broussolle</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Isnard</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Electroencephalogr Clin Neurophysiol</MedlineTA><NlmUniqueID>0375035</NlmUniqueID><ISSNLinking>0013-4694</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005073" MajorTopicYN="N">Evoked Potentials, Somatosensory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008475" MajorTopicYN="N">Median Nerve</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009127" MajorTopicYN="N">Muscle Rigidity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7688279</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001711 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001711 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:7688279
|texte= Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7688279" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |